PURE Bioscience Strengthens Sales and Marketing Organization
Commercialization Focus on Food Safety Segment
SAN DIEGO, CA -- (Marketwired) -- 08/28/13 -- PURE Bioscience
(OTCQB: PURE), creator of the patented silver dihydrogen citrate
(SDC) antimicrobial, today announced the strengthening of its sales
and marketing leadership team. The company appointed Cliff Wechsler
as its new Executive Vice President of Sales, and Tom Myers assumed
the position of Executive Vice President of Marketing and Product
Development. The company reported that the management change
established the leadership to drive the commercialization of SDC
technology in the food industry as a novel and proprietary
antimicrobial agent to protect consumer safety against various
Mr. Wechsler brings over 30 years of experience, having previously
served in a variety of high level sales management positions with
Kraft Foods. During his tenure at Kraft Foods Mr. Wechsler shaped and
developed the business strategy for their Quick Service Restaurant
(QSR) market segment.
Mr. Myers will now lead the company's marketing and product
development, having previously joined PURE in May 2011 as Executive
Vice President of Sales and Marketing. Mr. Myers brings over 40 years
of food industry experience, with emphasis on both food science and
food processing where he served in senior leadership positions in
marketing, product development and technical operations.
"Mr. Wechsler brings to PURE not only the level of industry expertise
to grow business but a demonstrative track record in developing and
transforming new businesses into high growth segments," stated Dave
Pfanzelter, Chairman and Chief Executive Officer of PURE. "This team
of experienced food industry executives provides us the focus and
discipline necessary to drive the commercial development of our
SDC-based products into the marketplace."
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based
bioscience products that provide solutions to numerous global health
challenges, including Staph (MRSA) and Carbapenem-resistant
Enterobacteriaceae (CRE)/NDM-1+. PURE's proprietary high efficacy/low
toxicity bioscience technologies, including its silver dihydrogen
citrate-based antimicrobials, represent innovative advances in
diverse markets and lead today's global trend toward industry and
consumer use of "green" products while providing competitive
advantages in efficacy and safety. Patented SDC is an
electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC
is distinguished from competitors in the marketplace because of its
superior efficacy, reduced toxicity and the inability of bacteria to
form a resistance to it. PURE is headquartered in El Cajon,
California (San Diego metropolitan area). Additional information on
PURE is available at www.purebio.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "expect," "intend," "project" or similar expressions.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's cash
position and liquidity requirements, the Company's failure to
implement or otherwise achieve the benefits of its proposed
initiatives and business plans, acceptance of the Company's current
and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive regulatory
approvals of such products, competitive factors, dependence upon
third-party vendors, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission.
By making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release.
Tom Hemingway, Redwood Investment Group
Peter C. Wulff, CFO & COO
Pure Bioscience, Inc.
Press spacebar to pause and continue. Press esc to stop.